[ Return to Index ]

Signet’s monoclonal prion antibody 6D11 available

Signet Laboratories, Inc. (Dedham, MA) a leading medical diagnostics/research company specializing in the development of monoclonal antibodies and diagnostic assays for cancer, infectious disease, and neurodegenerative disease, announced the availability of Monoclonal Prion Antibody 6D11, the newest addition to the neuroscience product line.

Prion diseases, or Transmissible Spongiform Encephalopathies, are degenerative diseases of the nervous system caused by transmissible particles that contain a pathogenic isoform of the prion protein, a normal constituent of cell membranes. These fatal diseases can affect bovine (BSE, Mad cow), sheep (Scrapie), deer and elk (CWD), and humans (vCJD). Although cross-species transmission of prion diseases seems to be limited by a "species barrier," the occurrence of bovine spongiform encephalopathy (BSE) and its transmission to humans indicate that animal prion diseases can pose a significant public health risk.

"The development of highly sensitive assays for ante mortem detection of misfolded prions is a top priority for minimizing the spread of the disease," stated Joe Bertelsen, Neuroscience Product Manager for Signet Laboratories. "Signet's new 6D11 antibody, in addition to Signet's existing prion antibody panel, gives researchers a powerful tool for developing such screening systems."

Signet is a leading medical diagnostics/research company specializing in the development of monoclonal antibodies and diagnostics assays for cancer, infectious disease, and neurodegenerative disease. Signet was created in 1989 as a commercial spinout of Johnson & Johnson's Cambridge Research Laboratories, Inc. (Cambridge, MA).

The company was founded to continue the mission originally established at Cambridge Research -- the early detection and recurrence monitoring of patients with cancer, infectious disease, and neurodegenerative disease. Signet has developed patented technology for diagnosis and recurrence monitoring and for risk assessment of asymptomatic patients in these areas. For more than a decade, the company has aggressively maintained licensing and development programs, which are responsible for its broad patent and intellectual estate.

Signet Laboratories, Inc.
+1-781-915-1404
www.signetlabs.com